Avanos Medical, Inc. Stockholders Approve Acquisition by American Industrial Partners
Click to view quick news summary (Spoiler)
Avanos Medical stockholders overwhelmingly approved the company's acquisition by American Industrial Partners (AIP) for $25.00 per share in cash, paving the way for the transaction to close by July 27, 2026.
Avanos Medical, Inc., a leading medical technology company, today announced that its stockholders have voted to approve the pending acquisition of Avanos by affiliates of investment funds advised by American Industrial Partners ("AIP") at a special meeting of stockholders (the "Special Meeting") held earlier today.
Based on preliminary voting results, approximately 99.75% of shares voted at the Special Meeting were voted in favor of the transaction, which represented approximately 74.96% of the total outstanding shares of Avanos common stock as of June 18, 2026, the record date for the Special Meeting.
"We are pleased with the outcome of the Special Meeting and thank our stockholders for their strong support," said Gary D. Blackford, Avanos' Board chair. "By partnering with AIP, we expect to build on our positive momentum with enhanced flexibility and resources, enabling Avanos to better address today's most pressing healthcare needs. We look forward to closing the transaction as Avanos enters the next chapter in its history."
As previously announced, pursuant to the terms of the merger agreement, Avanos stockholders will have the right to receive $25.00 per share in cash at the effective time of the acquisition for each share of Avanos common stock they own. All required regulatory approvals under the merger agreement have been received. The transaction is expected to close no later than July 27, 2026, subject to the satisfaction or waiver of customary closing conditions.
The final voting results of the Special Meeting will be set forth in a Current Report on Form 8-K to be filed by the Company with the U.S. Securities and Exchange Commission.
About Avanos Medical, Inc.
Avanos Medical, Inc. is a medical technology company focused on delivering clinically superior medical device solutions that will help patients get back to what matters. Headquartered in Alpharetta, Georgia, we are committed to addressing some of today's most important healthcare needs, including providing a vital lifeline for nutrition to patients from hospital to home, and reducing the use of opioids while helping patients move from surgery to recovery. Avanos develops, manufactures and markets its recognized brands globally and holds leading market positions in multiple categories across its portfolio.
